Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)
Kunshan, SD, CN
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate and high-risk myelofibrosis. It also develops drug candidates in the NDA, Phase III, or registration clinical trial stages, such as gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, ruxolitinib-intolerant and relapsed/refractory myelofibrosis, moderate to severe plaque psoriasiste, idiopathic pulmonary fibrosis, severe alopecia areata, nonsegmental vitiligo, and myelofibrosis; and recombinant human thyroid-stimulating hormone for injection. In addition, the company is developing drug candidates in Phase I/II clinical trial stages consisting of donafenib tablets for liver cancer and anti-tumor immunotherapy; gecacitinib hydrochloride cream for mild to moderate alopecia areata and atopic dermatitis, and nonsegmental vitiligo; ZG19018 and ZG2001 tablets for KRAS G12C and KRAS mutation late-stage solid tumors; and ZG005, ZGGS18, ZGGS15, ZG0895, and ZG006 powders for injections for late-stage solid tumors. Further, it develops pre-clinical drug candidates, including ZG1905 for topical bleeding; and ZGGS001 and GS11 powders for injections for late-stage tumors. The company’s products are used in multiple therapeutic areas, such as tumors, bleeding and blood diseases, and immune inflammatory diseases. Suzhou Zelgen Biopharmaceuticals Co., Ltd. was founded in 2009 and is based in Kunshan, the People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.23% | -1.54% | -3.91% | +21.69% | -9.15% | +7.80% | -8.12% | +85.40% | +20.69% | +33.97% | +33.97% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+52.5% ★ Q1'26: +440.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-19.2% Q1'26: +2,272.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-19.6% Q1'26: +92.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-30.4% Q1'26: +69.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-121.1% Q1'26: +3,818.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.6% ★ Q1'26: +3.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-6.04× Q1'26: 0.41× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
190.36M
est: 208.00M (-8.5%)
|
302.31M
est: 304.00M (-0.6%)
|
386.44M
est: 407.21M (-5.1%)
|
532.95M
est: 638.06M (-16.5%)
|
812.73M
est: 817.87M (-0.6%)
|
2.07B
1.99B – 2.15B
+153.1% YoY
|
2.18B
1.52B – 3.09B
+5.3% YoY
|
2.73B
2.68B – 2.79B
+25.4% YoY
|
| EBITDA |
-416.69M
est: -176.66M (-135.9%)
|
-420.51M
est: -258.20M (-62.9%)
|
-232.72M
est: -243.76M (+4.5%)
|
-83.03M
est: -381.95M (+78.3%)
|
-191.04M
est: -489.59M (+61.0%)
|
-1.24B
-1.28B – -1.19B
-153.1% YoY
|
-1.30B
-1.85B – -912.80M
-5.3% YoY
|
-1.64B
-1.67B – -1.61B
-25.4% YoY
|
| EBIT |
-458.95M
est: -183.34M (-150.3%)
|
-473.01M
est: -267.96M (-76.5%)
|
-274.63M
est: -264.72M (-3.7%)
|
-125.95M
est: -414.80M (+69.6%)
|
-246.65M
est: -531.69M (+53.6%)
|
-1.35B
-1.39B – -1.30B
-153.1% YoY
|
-1.42B
-2.01B – -991.29M
-5.3% YoY
|
-1.78B
-1.81B – -1.74B
-25.4% YoY
|
| Net Income |
-451.00M
est: -437.35M (-3.1%)
|
-457.33M
est: -409.52M (-11.7%)
|
-278.58M
est: -230.89M (-20.7%)
|
-137.83M
est: -144.10M (+4.3%)
|
-162.95M
est: -106.72M (-52.7%)
|
616.04M
595.61M – 636.48M
+677.3% YoY
|
343.37M
193.77M – 492.96M
-44.3% YoY
|
377.07M
324.17M – 555.71M
+9.8% YoY
|
| SGA |
213.57M
est: 278.55M (-23.3%)
|
310.95M
est: 407.11M (-23.6%)
|
263.52M
est: 314.57M (-16.2%)
|
327.50M
est: 492.90M (-33.6%)
|
337.73M
est: 631.80M (-46.5%)
|
1.60B
1.54B – 1.66B
+153.1% YoY
|
1.68B
1.18B – 2.39B
+5.3% YoY
|
2.11B
2.07B – 2.15B
+25.4% YoY
|
| EPS |
-1.88
est: -1.65 (-13.9%)
|
-1.91
est: -1.55 (-23.6%)
|
-1.09
est: -0.87 (-24.9%)
|
-0.52
est: -0.59 (+11.9%)
|
-0.62
est: -0.39 (-59.6%)
|
2.32
2.26 – 2.42
+697.1% YoY
|
1.22
0.74 – 1.87
-47.3% YoY
|
1.67
1.23 – 2.11
+36.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Binhua Lyu | Deputy GM, EVice President of Chemistry & Director | — | male |
| Gang Huang | Chief Financial Officer & Deputy GM | — | male |
| Huiping Lu | Executive Vice President & Director | — | female |
| Jisheng Wu | Director & Deputy GM | — | male |
| Qingping Gao | Deputy GM & Board Secretary | — | female |
| Shice Shao | Accounting Supervisor | — | — |
| Zelin Sheng | Chairman of the Board & GM | — | male |
| Zeqi Sheng | Chief Scientific Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688266.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
